Abstract: Methods and compositions for treating cancer are disclosed. The compositions comprise immune cells pretreated with ponatinib, or immune cells co-administered with ponatinib, where ponatinib promotes survival and anti-cancer cytotoxicity of the immune cells.

Abstract: The present invention relates to a cell therapeutic agent comprising a stem cell expressing Lin28, a pharmaceutical composition comprising a stem cell expressing Lin28 for the prevention or treatment of a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder, and a method for treating a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder using the composition. A stem cell excellent in terms of differentiation potency to various tissue cells and renewal ability can be prepared by introducing Lin28, which regulates an embryonic development procedure, or a vector expressing Lin28 during stem cell culturing, and by culturing the cell.

Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.

Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.

Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.

Abstract: Methods and compositions for treating cancer are disclosed. The compositions comprise immune cells pretreated with ponatinib, or immune cells co-administered with ponatinib, where ponatinib promotes survival and anti-cancer cytotoxicity of the immune cells.

Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.

Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.

Abstract: The present invention relates to a cell therapeutic agent comprising a stem cell expressing Lin28, a pharmaceutical composition comprising a stem cell expressing Lin28 for the prevention or treatment of a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder, and a method for treating a neurological disorder, a bone disorder, a muscular system disorder, an epithelium-related disorder or a blood-related disorder using the composition. A stem cell excellent in terms of differentiation potency to various tissue cells and renewal ability can be prepared by introducing Lin28, which regulates an embryonic development procedure, or a vector expressing Lin28 during stem cell culturing, and by culturing the cell.

Abstract: A mobile terminal includes a wireless communication unit establishing a first communication session with a first entity and a second communication session with a second entity, a display displaying a plurality of windows including a first window and a second window, a memory storing a merging menu, and a controller controlling the display to display the first window related to the first communication session and the second window related to the second communication session, the controller generating a third window including the first communication session and the second communication session in response to a an input and controlling the display to display the third window further including the first entity and the second entity.

Abstract: A method for controlling display of a messaging window displays a messaging window including a message input region and a message output region, receives a plurality of incoming messages which are successively displayed in the message output region, and selectively freezes the message output region such that incoming messages that are received while the message output region is selectively frozen are not displayed in the message output region.

Abstract: A mobile terminal includes a wireless communication unit establishing a first communication session with a first entity and a second communication session with a second entity, a display displaying a plurality of windows including a first window and a second window, a memory storing a merging menu, and a controller controlling the display to display the first window related to the first communication session and the second window related to the second communication session, the controller generating a third window including the first communication session and the second communication session in response to a an input and controlling the display to display the third window further including the first entity and the second entity.

Abstract: A method for controlling display of a messaging window displays a messaging window including a message input region and a message output region, receives a plurality of incoming messages which are successively displayed in the message output region, and selectively freezes the message output region such that incoming messages that are received while the message output region is selectively frozen are not displayed in the message output region.

Abstract: Disclosed is a novel healthy and functional food having an obesity-suppressing activity. The healthy and functional food according to the present invention is manufactured by using an extract or a raw juice of purple-colored potato as a main/minor ingredient, or by adding the extract or a raw juice of purple-colored potato to various favorite foods. The extract of purple-colored potato according to the present invention has an obesity-suppressing activity by preventing an adipose cell from being differentiated and reducing leptin protein aiding to differentiate into adipose cells, and has an ability to reduce free fatty acid which is a hyperlipidemia-inducing factor and cholesterol in blood. Therefore, the healthy and functional food containing the extract of purple-colored potato according to the present invention can be useful to treat obesity patients including a wide age group of teenagers and adults and old persons.

Abstract: The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers or as an ancillary(auxiliary) means of the same.

Abstract: The present invention relates to a composite electrolyte membrane for fuel cells that has high proton conductivity and low fuel permeability even under low humidity conditions and at elevated temperatures. The membrane, comprising a cation exchange resin and acid-treated dendrimers, has great utility in large and medium fuel cells for applications in household appliances, electric vehicles, etc.

Abstract: A water purifier that assures easier change of a used filter comprises a base, at least one filter replaceably attached to the base and including a first end with a first fluid port and a second end with a second fluid port, a first connector supporting the first end of the filter in a separable manner and including a connector port connected to the first fluid port of the filter, a second connector spaced apart from the first connector to accomodate the filter therebetween and including a bore aligned with the second fluid port of the filter, a spool fitted into the bore of the second connector for movement between an extended position allowing fluid flow and a contracted position preventing fluid flow, and a spool actuator for slidingly moving the spool between the extended position and the contracted position.

Abstract: Toxic contaminants dispersed throughout a section of earth can be removed by a process that includes applying liquid hydrogen peroxide to the earth surface, and exerting a vacuum force on the earth at a depth where the earth is relatively uncontaminated. The vacuum force evacuates the earth pores, to augment the gravitational force on the liquid hydrogen peroxide, so that the liquid is enabled to flow through the earth to chemically react with toxic contaminants. One or more vacuum pumps are connected with underground perforated pipes bordering the treated earth section, to produce the necessary vacuum force on the liquid hydrogen peroxide.